Jiacong Guo

Co-Founder

2022

Cofounder of BeiCell Therapeutics, incubated by BioTrack Capital, a revolutionary cell therapy company stemming from Prof. Hongkui Deng’s lab at Peking University, aiming to provide completely off-the-shelf cell therapy for cancer, autoimmune diseases treatment and regenerative medicine.

Executive Director

2022

Healthcare Investment with 1.5B USD(10B RMB)AUM Primarily focused on biotech& pharmaceutical companies in early growth stage Fund raising, deal sourcing, due diligence, post-investment management and exit Directed the investment of: Asieris(SH:688176) BioNova,LaNova,Shanton,Innogen,Pyrotech,OnCusp, Abogen, Gritscience,ExiCure,Brise,Cytovia&Cytolynx Parcitipated in the investment of: Exegenesis, OBio

Vice President

2019 - 2021

Board Member

2021

Member Of The Supervisory Board

2020

A leading biopharma which specializes in developing long lasting human GLP-1RA drugs for Type 2 Diabetes, Overweight and Cardiovascular patients

Board Member

2020

An innovative biotech company which develops first-in-class drugs for patients suffering from metabolic diseases such as gout, pruritis, etc

Assistant Director at CEO Office

2018 - 2019

Corporate Strategy and Investment Portofolio company: NASDAQ-listed company Inhibrx(INBX) Virtuoso

Investment Intern

2018 - 2018

Performed Due Diligence on 20+ projects within 3 months

Research Scientist

2017 - 2018

Worked in the core team who developed the first anti-PD1 antibody in the world-Nivolumab(trade name: Opdivo) Novel T cell immuno-oncology target discovery and mechanism of action study Monoclonal antibody screening and validation by functional assays Stable cell line generation by lentiviral transduction and CRISPR Diagnostic biomarker discovery& validation for IHC Pathology research

Research Assistant

2011 - 2017

Therapeutic Monoclonal Antibody Development Tumor Microenvironment Research